Defining Potentially Inappropriate Prescriptions for Hypoglycaemic Agents to Improve Computerised Decision Support: A Study Protocol.

decision support systems hypoglycaemic agents inappropriate prescribing methodology research potentially inappropriate prescriptions study protocol type 2 diabetes

Journal

Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525

Informations de publication

Date de publication:
11 Nov 2021
Historique:
received: 06 10 2021
revised: 05 11 2021
accepted: 07 11 2021
entrez: 27 11 2021
pubmed: 28 11 2021
medline: 28 11 2021
Statut: epublish

Résumé

In France, around 5% of the general population are taking drug treatments for diabetes mellitus (mainly type 2 diabetes mellitus, T2DM). Although the management of T2DM has become more complex, most of these patients are managed by their general practitioner and not a diabetologist for their antidiabetics treatments; this increases the risk of potentially inappropriate prescriptions (PIPs) of hypoglycaemic agents (HAs). Inappropriate prescribing can be assessed by approaches that are implicit (expert judgement based) or explicit (criterion based). In a mixed, multistep process, we first systematically reviewed the published definitions of PIPs for HAs in patients with T2DM. The results will be used to create the first list of explicit definitions. Next, we will complete the definitions identified in the systematic review by conducting a qualitative study with two focus groups of experts in the prescription of HAs. Lastly, a Delphi survey will then be used to build consensus among participants; the results will be validated in consensus meetings. We developed a method for determining explicit definitions of PIPs for HAs in patients with T2DM. The resulting explicit definitions could be easily integrated into computerised decision support tools for the automated detection of PIPs.

Identifiants

pubmed: 34828585
pii: healthcare9111539
doi: 10.3390/healthcare9111539
pmc: PMC8622925
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : French National Agency for Research
ID : ANR-18-IBHU-0001
Organisme : Fonds européen de développement régional
ID : NP0025517
Organisme : Hauts-de-France Regional Council
ID : 20001891/NP0025517
Organisme : European Metropolis of Lille
ID : 2019_ESR_11

Références

Diabetes Metab. 2020 Nov;46(6):472-479
pubmed: 31923577
J Clin Epidemiol. 2017 Jul;87:4-13
pubmed: 28529184
Age Ageing. 2017 Jul 1;46(4):607-613
pubmed: 28064169
N Engl J Med. 1977 Jan 20;296(3):170-2
pubmed: 556639
J Diabetes Complications. 2016 May-Jun;30(4):675-80
pubmed: 26900098
BMJ Open Diabetes Res Care. 2021 May;9(1):
pubmed: 33941550
BMC Geriatr. 2020 Sep 24;20(1):367
pubmed: 32972389
Int J Clin Pract. 2017 Jan;71(1):
pubmed: 27981681
BMJ. 2008 Jul 31;337:a744
pubmed: 18669566
Age Ageing. 2017 Jul 1;46(4):600-607
pubmed: 28119312
Eur J Clin Pharmacol. 2015 Dec;71(12):1525-33
pubmed: 26407684
Br J Clin Pharmacol. 2018 Nov;84(11):2600-2614
pubmed: 30007041
Int J Antimicrob Agents. 2017 Nov;50(5):640-648
pubmed: 28803931
Diabetes Obes Metab. 2018 Apr;20(4):1066-1069
pubmed: 29193555
J Diabetes Complications. 2018 Apr;32(4):444-450
pubmed: 29274807
Trials. 2012 Aug 06;13:132
pubmed: 22867278
Lancet. 2007 Jul 14;370(9582):173-184
pubmed: 17630041
BMC Geriatr. 2011 Nov 30;11:79
pubmed: 22129458
J Am Geriatr Soc. 2019 Apr;67(4):674-694
pubmed: 30693946
Diabetes Obes Metab. 2014 Dec;16(12):1192-203
pubmed: 25073699
BMC Geriatr. 2009 Jan 28;9:5
pubmed: 19175914
Pharmacol Res Perspect. 2020 Aug;8(4):e00621
pubmed: 32618136
Diabetes Care. 2020 Dec;43(12):2967-2974
pubmed: 33046501
Pharmacoepidemiol Drug Saf. 2012 Oct;21(10):1053-9
pubmed: 22002240
Presse Med. 2019 Mar;48(3 Pt 1):238-242
pubmed: 30853280
Drugs Aging. 2005;22(9):767-77
pubmed: 16156680
JPEN J Parenter Enteral Nutr. 2021 Mar;45(3):625-632
pubmed: 32384187
Clin Interv Aging. 2017 Aug 30;12:1379-1389
pubmed: 28919724
BMJ Open. 2019 Jul 19;9(7):e025784
pubmed: 31326925

Auteurs

Paul Quindroit (P)

Univ. Lille, CHU Lille, ULR 2694-METRICS: Évaluation des Technologies de Santé et des Pratiques Médicales, F-59000 Lille, France.

Nicolas Baclet (N)

Univ. Lille, CHU Lille, ULR 2694-METRICS: Évaluation des Technologies de Santé et des Pratiques Médicales, F-59000 Lille, France.
Lille Catholic Hospitals, Department of Infectious Diseases, F-59000 Lille, France.

Erwin Gerard (E)

Univ. Lille, CHU Lille, ULR 2694-METRICS: Évaluation des Technologies de Santé et des Pratiques Médicales, F-59000 Lille, France.
CHU Lille, Institut de Pharmacie, F-59000 Lille, France.

Laurine Robert (L)

Univ. Lille, CHU Lille, ULR 2694-METRICS: Évaluation des Technologies de Santé et des Pratiques Médicales, F-59000 Lille, France.
CHU Lille, Institut de Pharmacie, F-59000 Lille, France.

Madleen Lemaitre (M)

CHU Lille, Department of Diabetology, Endocrinology, Metabolism and Nutrition Lille University Hospital, F-59000 Lille, France.
School of Medicine, Lille University, F-59000 Lille, France.

Sophie Gautier (S)

CHU Lille, Centre Régional de Pharmacovigilance, F-59000 Lille, France.

Chloé Delannoy-Rousselière (C)

CHU Lille, Institut de Pharmacie, F-59000 Lille, France.

Bertrand Décaudin (B)

CHU Lille, Institut de Pharmacie, F-59000 Lille, France.
Univ. Lille, CHU Lille, ULR 7365-GRITA: Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000 Lille, France.

Anne Vambergue (A)

CHU Lille, Department of Diabetology, Endocrinology, Metabolism and Nutrition Lille University Hospital, F-59000 Lille, France.
European Genomic Institute for Diabetes, University School of Medicine Lille, F-59000 Lille, France.

Jean-Baptiste Beuscart (JB)

Univ. Lille, CHU Lille, ULR 2694-METRICS: Évaluation des Technologies de Santé et des Pratiques Médicales, F-59000 Lille, France.

Classifications MeSH